Discover trends, market shifts, and competitive outlooks for the bi-specific mabs industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

#How Has The Bi-Specific MAbS Market Size Shifted, And What Is the Outlook Through 2034?

The market size of bi-specific MAbS has witnessed a swift expansion in the past few years. The market which is projected to climb from $7.83 billion in 2024 to $9.1 billion in 2025, echoes a compound annual growth rate (CAGR) of 16.2%. Factors such as elevated healthcare expenditure, augmented funding and various government schemes have contributed to the growth observed in the historical phase.

The market size of bi-specific MAbS is anticipated to witness a swift expansion in the coming years. The market is projected to reach $15.19 billion in 2029, with a compound annual growth rate (CAGR) of 13.7%. This growth during the forecasted period can be credited to the rising incidence of cancer, heightened aging populace, and a surge in chronic disease prevalence. The key trends predicted for this period involve an emphasis on technological progress, product novelty, the use of artificial intelligence, investment in specialized and combination therapy, as well as tactical collaborations.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3390&type=smp

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Bi-Specific MAbS Market?

The escalating incidence of cancer and other chronic diseases is expected to fuel the expansion of the bispecific monoclonal antibodies market in the predicted timeline. Bispecific monoclonal antibodies, designed for treating various cancers, infectious diseases, disorders of the central nervous system, and autoimmune disorders, are deemed more potent than monoclonal antibodies (moAbs) as they target multiple tumor antigens on cells to hinder the progression of cancer. As an example, the Cancer Facts & Figures 2023 report by the American Cancer Society (ACS), a voluntary health institution based in the US, predicts about 609,820 cancer-related deaths in the US in 2023. Thus, an escalating count of chronic diseases, including cancer, is expected to drive the demand for bi-specific MAbs as an effective treatment for these diseases.

Which Key Market Segments Comprise the Bi-Specific MAbS Market and Drive Its Revenue Growth?

The bi-specific MAbS market covered in this report is segmented –

1) By Type: Catumaxomab (Removab), Blinatumomab, Duligotumab, Emicizumab, Amivantamab, Faricimab, Teclistamab

2) By Product Type: In Vivo, In Vitro

3) By Indication: Cancer, Haemophilia A, Ophthalmic

4) By End Use: Hospitals, Research Institutes, Other End-Users

Subsegments:

1) By Catumaxomab (Removab): Cancer Therapy, Targeting EpCAM and CD3

2) By Blinatumomab: Acute Lymphoblastic Leukemia (ALL) Treatment, Targeting CD19 and CD3

3) By Duligotumab: Oncology Treatments, Targeting Epidermal Growth Factor Receptor (EGFR)

4) By Emicizumab: Hemophilia A Treatment, Targeting Factor IXa and Factor X

5) By Amivantamab: Non-Small Cell Lung Cancer (NSCLC) Therapy, Targeting EGFR And MET

6) By Faricimab: Ophthalmology Treatment (Wet Age-related Macular Degeneration, Diabetic Macular Edema), Targeting Angiopoietin-2 And VEGF-A

7) By Teclistamab: Multiple Myeloma Treatment, Targeting BCMA and CD3

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=3390&type=smp

Which Areas Are Leading Regions in the Bi-Specific MAbS Market Expansion Across the Globe?

North America was the largest region in the bi-specific MAbs market in 2024. The regions covered in the bi-specific MAbs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Are the Key Market Trends in theBi-Specific MAbS Market Over the Coming Years?

Firms operating in the bi-specific MAbs market are progressively investing in strategic initiatives like partnerships and collaborations to broaden their product range and enhance their global footprint. A strategic alliance is a cooperative arrangement between two or more entities aimed at achieving shared objectives. For instance, in October 2022, Gilead Sciences and MacroGenics, both US-based biopharmaceutical corporations, announced an exclusive collaboration to work on MGD024, a bispecific antibody aimed at CD123 and CD3, using MacroGenics’ DART platform, as well as two other bispecific research programs. The partnership gives Gilead the exclusive option to license MGD024, with potential applications in treating a variety of hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Moreover, MGD024 is engineered to reduce cytokine-release syndrome (CRS) and enable intermittent dosing, which could lead to more patient-friendly treatment protocols and enhanced clinical outcomes for AML and MDS patients.

View the full report here:

https://www.thebusinessresearchcompany.com/report/bi-specific-mab-global-market-report

How Is the Bi-Specific MAbS Market Conceptually Defined?

Bi-specific MAbs or bispecific monoclonal antibodies refer to antibodies that have two binding sites and are designed to bind to two antigens that are either distinct or have two different epitopes. Monoclonal antibodies (MoAbs) do not have the clinical therapeutic effects of BsAbs, which have a wide range of applications for the treatment of different diseases as well as tumor immunotherapy.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3390

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model